(The following is a reformatted version of a press release
issued by AstraZeneca PLC and received via electronic mail. The
release was confirmed by the sender.)
US APPEALS COURT ISSUES A TEMPORARY INJUNCTION PENDING APPEAL
AGAINST DISTRIBUTION OF GENERIC PULMICORT RESPULES®
(Budesonide Inhalation Suspension)
24 May 2013
AstraZeneca today announced that the US Court of Appeals for the
Federal Circuit issued a temporary injunction blocking generic
manufacturers from distributing generic versions of PULMICORT
RESPULES in the US until the Court rules on AstraZeneca’s appeal
of a District Court decision that found one patent protecting
the product to be invalid and another patent not infringed. As
a condition of the injunction, the Court has also ordered that
AstraZeneca post a bond in the amount of $72 million.
“We intend to vigorously defend the intellectual property rights
protecting PULMICORT RESPULES.” said Paul Hudson, Executive Vice
President, North America.
The patents protecting PULMICORT RESPULES expire in 2018, with
paediatric exclusivity extending into 2019.
AstraZeneca is a global, innovation-driven biopharmaceutical
business that focuses on the discovery, development and
commercialisation of prescription medicines, primarily for the
treatment of cardiovascular, metabolic, respiratory,
inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.
For more information please visit: www.astrazeneca.com
Esra Erkal-Paler +44 20 7604 8030 (UK/Global)
Vanessa Rhodes +44 20 7604 8037 (UK/Global)
Ayesha Bharmal +44 20 7604 8034 (UK/Global)
Tony Jewell +1 (302) 885 2677 (US)
Jacob Lund +46 8 553 260 20 (Sweden)
James Ward-Lilley +44 20 7604 8122 mob: +44 7785 432613
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Colleen Proctor + 1 302 886 1842 mob: +1 302 357 4882
Ed Seage + 1 302 886 4065 mob: +1 302 373 1361
Press spacebar to pause and continue. Press esc to stop.